Sodium glucose transporter 2 inhibitors for heart failure
World Journal of Cardiology 2026 Open access
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT
Free to try with your Science Catalogs account.
Abstract
Heart failure (HF) is a leading cause of cardiovascular morbidity and mortality, affecting over 64 million individuals worldwide. Despite advances in guideline-directed medical therapy, patients with HF continue to experience poor outcomes, highlighting the need for novel therapeutic approaches. Sodium glucose transporter 2 (SGLT2) inhibitors, initially developed for diabetes management, have emerged as groundbreaking therapies for HF. These agents demonstrate remarkable cardiovascular benefits that extend beyond their glucose-lowering effects, including significant reductions in HF hospitalization and cardiovascular mortality rates. Landmark trials including Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure, Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction, Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction, and Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure have established the efficacy of SGLT2 inhibitors across the spectrum of HF phenotypes, regardless of diabetes status. The mechanisms underlying these benefits are multifaceted, involving improvements in cardiac energetics, mitochondrial function, reduction of oxidative stress, attenuation of inflammation, and favorable effects on cardiac remodeling and fibrosis. This comprehensive review examines the current evidence supporting the use of SGLT2 inhibitors in HF management, explores the mechanistic pathways responsible for their cardiovascular benefits, analyzes key clinical trial data, and discusses future prospects for this transformative drug class in cardiovascular medicine.
Fields of Study & Subjects
Heart Failure Treatment and Management
Diabetes Treatment and Management
Cardiovascular Function and Risk Factors
Publication details
- Journal / source
- World Journal of Cardiology
- Volume
- 18
- Issue
- 3
- Publication date
- 23 March 2026
- Language
- EN